Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Neuropeptide levels in the basal ganglia of aged common marmosets following prolonged treatment with MPTP

  • 27 Accesses

  • 19 Citations

Summary

Aged common marmosets were treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP; 0.5–2.0 mg/kg/week i.p.) for 16 or 24 weeks, observed for a total of 30 weeks and then killed for measurement of biochemical pramaters in basal ganglia. The MPTP treatment induced a marked depletion in dopamine, 3,4-dihydroxyphenylacetic acid and homovanillic acid levels in the caudate nucleus and putamen. In contrast, the concentrations of five neuropeptides: [Met5]-enkephalin, [Leu5]-enkephalin, cholecystokinin, substance P and neurotensin as measured by a combined HPLC/RIA method, remained unaltered in all basal ganglia regions examined. Enkephalin precursor levels, as reflected by cryptic [Met5]-enkephalin content, were increased in the putamen, but not in the caudate nucleus, as a consequence of MPTP administration. Cryptic [Leu5]-enkephalin content remained unchanged in the striatum of MPTP treated marmosets. Overall, these results suggest an increase in striatal [Met5]-enkephalin release following chronic MPTP treatment of aged marmosets. However, the chronic treatment of aged marmosets with MPTP does not reproduce the neuropeptide alterations characteristic of Parkinson's disease.

This is a preview of subscription content, log in to check access.

References

  1. Agid Y, Javoy-Agid F (1985) Peptides and Parkinson's disease. Trends Neurosci 6: 30–35

  2. Allen JM, Cross AJ, Yeats JC, Ghatei MA, McGregor GP, Close SP, Pay S, Marriott AS, Tyers MB, Crow TJ, Bloom SR (1986) Neuropeptides and dopamine in the marmoset. Effect of treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): an animal model for Parkinson's disease? Brain 109: 143–157

  3. Angulo JA, Davis LG, Burkhart BA, Christoph GR (1986) Reduction of striatal dopaminergic neurotransmission elevates striatal proenkephalin mRNA. Eur J Pharmacol 130: 341–343

  4. Bissette G, Nemeroff CB, Decker MW, Kizer JS, Agid Y, Javoy-Agid F (1985) Alterations in regional brain concentrations of neurotensin and bombesin in Parkinson's disease. Ann Neurol 17: 324

  5. Burns RS, Chiueh CC, Markey SP, Ebert MN, Jacobowitz DM, Kopin IJ (1983) A primate model of parkinsonism; selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci 80: 4546–4550

  6. Cupo A, Pontarotti PA, Jarry Th, Delaage M (1984) A new immunological approach to the detection and the quantitation of the Met5-enkephalin precursors in rat brain. Neuropeptide 4: 375–387

  7. De Ceballos ML, Boyce S, Taylor M, Jenner P, Marsden CD (1987) Age-related decreases in the concentration of Met-and Leu-enkephalin and neurotensin in the basal ganglia of rats. Neurosci Lett 75: 113–117

  8. Forno LS, Langston JW, Delanney LE, Irwin I (1988) An electron microscopic study of MPTP-induced inclusion bodies in an old monkey. Brain Res 448: 150–157

  9. Grafe MR, Forno S, Enge LF (1985) Immunocytochemical studies of substance P and met-enkephalin in the basal ganglia and substantia nigra in Huntington's, Parkinson's and Alzheimer's disease. J Neuropathol Exp Neurol 44: 47

  10. Hornykiewicz O (1980) Biochemical abnormalities in some extra-striatal neuronal systems in Parkinson's disease. In: Rinne UK, Kingler M, Stamm G (eds) Parkinson's disease: current progress, problems and management. Elsevier/North Holland, Amsterdam, pp 107–120

  11. Jenner P, Rupniak NMJ, Rose S, Kelly E, Kilpatrick G, Lees A, Marsden CD (1984) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset. Neurosci Lett 50: 85–90

  12. Jenner P, Taquet H, Mauborgne A, Benoliel JJ, Cesselin F, Rose S, Javoy-Agid F, Agid Y, Marsden CD (1986) Lack of change in basal ganglia neuropeptide content following subacute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of the common marmoset. J Neurochem 47: 1548–1551.

  13. Jiang H-K, McGinty JF, Hong JS (1990) Differential modulation of striatonigral dynorphin and enkephalin by dopamine receptor subtypes. Brain Res 507: 57–64

  14. Liston D, Patey G, Rossier J (1984) Processing of proenkephalin is tissue-specific. Science 225: 734–736

  15. Sivam SP, Breese GR, Krause JE, Napier TC, Mueller RA, Hong JS (1987) Neonatal and adult 6-hydroxydopamine-induced lesional differentially alter tachykinin and enkephalin gene expression. J Neurochem 49: 1623–1633

  16. Smith Y, Parent A (1986) Differential connections of caudate nucleus and putamen in the squirrel monkey (Samiri Sciureus). Neuroscience 18: 347–371

  17. Taquet H, Javoy-Agid F, Mauborgne A, Benoliel JJ, Agid Y, Legrand JC, Hamon H, Cesselin F (1987) Brain neuropeptides in progressive supranuclear palsy. Brain Res 411: 178–182

  18. Taquet H, Nomoto M, Rose S, Jenner P, Javoy-Agid F, Mauborgne A Benoliel JJ, Marsden CD, Legrand JC, Agid Y, Hamon M, Cesselin F (1988) Levels of MET-enkephalin, LEU-enkephalin, substance P and cholecystokinin in the brain of the common marmoset following long term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment. Neuropeptides 12: 105–110

  19. Vernier P, Julien JF, Rataboul P, Fourrier O, Feuerstein C, Mallet J (1988) Similar time course changes in striatal levels of glutamic acid decarboxylase and proenkephalin mRNA following dopaminergic deafferentation in the rat. J Neurochem 51: 1375–1380

  20. Wagner J, Vitali P, Palfreyman MG, Zraika M, Huol S (1982) Simultaneous determination of 3,4-dihydroxyphenylalanine, 5-hydroxy-tryptophan, dopamine, 4-hydroxy-3-methoxyphenylalanine, norepinephrine, 3,4-dihydroxyphenyl-acetic acid, homovanillic acid, serotonin and 5-hydroxyindoleacetic acid in rat cerebrospinal fluid and brain by high performance liquid chromatography with electrochemical detection. J Neurochem 38: 1241–1254

  21. Waters CM, Peck R, Rossor M, Reynold GP, Hunt SP (1988) Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea. Neuroscience 25: 419–438

  22. Young SW, Bonner TI, Brann MR (1986) Mesencephalic dopamine neurons regulate the expression of neuropeptides mRNAs in the rat forebrain. Proc Natl Acad Sci USA 83: 9827–9831

  23. Zamir N, Skofitsch G, Bannon MJ, Helke CJ, Kopin IJ, Jacobowitz DM (1984a) Primate model of Parkinson's disease: alterations in multiple opoid systems in the basal ganglia. Brain Res 322: 356–360

  24. Zamir N, Palkovitz M, Weber H, Mezey E, Brownstein MJ (1984b) A dynorphinergic pathway of Leu-enkephalin production in substantia nigra. Nature 307: 643

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Taylor, M.D., de Ceballos, M.L., Rose, S. et al. Neuropeptide levels in the basal ganglia of aged common marmosets following prolonged treatment with MPTP. J Neural Transm Gen Sect 3, 99–108 (1991). https://doi.org/10.1007/BF02260885

Download citation

Keywords

  • MPTP
  • peptides
  • basal ganglia
  • common marmoset
  • Parkinson's disease